Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis

Affiliations

• ¹ Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children's Hospital, Medical School, National and Kapodistrian University of Athens, and Pediatric Faculty, Medical School, University of Cyprus, Nicosia, Cyprus; dmaritsi@gmail.com.
• ² Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children's Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
• ³ UCL-Great Ormond Street-Institute of Child Health, Infection, Immunity, Inflammation and Physiological Medicine, London, UK.